سعر اندوراسيروكس 500مجم 20قرص 2022

Tablets for oral suspension (dispersible) containing deferasirox 500 mg (Al Andalous Pharmaceutical Industries), an oral iron chelator for chronic iron overload; 20 tablets per pack.

• Chronic iron overload due to blood transfusions (transfusional haemosiderosis)Population: Patients 2 years of age and olderDailyMed (U.S. National Library of Medicine)
• Chronic iron overload in non-transfusion-dependent thalassaemia syndromes (LIC >=5 mg Fe/g dw and serum ferritin >300 mcg/L)Population: Patients 10 years of age and olderDailyMed (U.S. National Library of Medicine)

• Most common (>5%): diarrhoea, vomiting, nausea, abdominal pain, skin rashes and increases in serum creatinine; in NTDT also increased transaminases.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• eGFR <40 mL/min/1.73 m2; poor performance status; high-risk myelodysplastic syndromes; advanced malignancies; platelet counts <50 x 10^9/L; known hypersensitivity to deferasirox or any component.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: acute kidney injury including renal failure requiring dialysis and renal tubular toxicity (some fatal); hepatic toxicity including failure (some fatal), mostly in patients >55 years or with comorbidities; gastrointestinal haemorrhage (some fatal), especially in elderly patients with advanced haematologic malignancies and/or low platelets.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Bone marrow suppression (neutropenia, agranulocytosis, worsening anaemia, thrombocytopenia); age-related toxicity in elderly and paediatric patients (monitor closely, avoid volume depletion in children); serious hypersensitivity; severe skin reactions (SJS, TEN, DRESS); auditory and ocular abnormalities; overchelation.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Film-coated and dispersible deferasirox tablets have different pharmacokinetic profiles: a 30% lower dose of the film-coated tablets is needed compared with the recommended dose of dispersible tablets; do not switch mg-for-mg.International label, equivalent formulation · European Medicines Agency (EMA)

• Aluminium-containing antacidsDo not take together.DailyMed (U.S. National Library of Medicine)
• Repaglinide and other CYP2C8 substratesDeferasirox increases repaglinide exposure; avoid; if unavoidable reduce repaglinide dose and monitor glucose.DailyMed (U.S. National Library of Medicine)
• Theophylline and other CYP1A2 substratesDeferasirox increases theophylline exposure; avoid; if unavoidable monitor levels and consider dose reduction.DailyMed (U.S. National Library of Medicine)

• Limited human data; use during pregnancy only if the potential benefit justifies the potential fetal risk. Hormonal contraceptives may be less effective - use non-hormonal contraception.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Advise women not to breastfeed during treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Deferasirox: Orally active chelator highly selective for iron (Fe3+); a tridentate ligand binding iron with high affinity in a 2:1 ratio; the iron complex is excreted mainly in the faeces (US label).